Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis C

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 190 articles:
HTML format



Single Articles


    November 2021
  1. GIADANS CG, Rios DA, Ameigeiras B, Haddad L, et al
    Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same.
    J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13635.
    PubMed     Abstract available


  2. FORNS X, Colom J, Garcia-Retortillo M, Quer JC, et al
    Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination.
    J Viral Hepat. 2021 Nov 22. doi: 10.1111/jvh.13634.
    PubMed     Abstract available


  3. MOHAMED EI, El-Ghnam SM, Bayoumi AM, Abdel-Mageed SM, et al
    Electronic Nose versus Quadrupole Mass Spectrometry for Identifying Viral Hepatitis C Patients.
    J Viral Hepat. 2021 Nov 12. doi: 10.1111/jvh.13630.
    PubMed     Abstract available


  4. CHIDWICK K, Myton R, Rodgers A, Jun M, et al
    A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial).
    J Viral Hepat. 2021 Nov 11. doi: 10.1111/jvh.13629.
    PubMed     Abstract available


    October 2021
  5. JUGNARAIN DV, Halford R, Smith S, Hickman M, et al
    Role of peer support in a hepatitis C elimination program.
    J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13626.
    PubMed     Abstract available


  6. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
    Serum alpha-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
    J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13625.
    PubMed     Abstract available


    September 2021
  7. NISHIGUCHI J, McNamara A, Surlyn CS, Eagen KV, et al
    Efficacy of an eConsult Service to Cure Hepatitis C in Primary Care.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13616.
    PubMed     Abstract available


  8. COPPOLA C, Masarone M, Bartoli M, Staiano L, et al
    Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13623.
    PubMed     Abstract available


  9. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
    Letter in response: Psychiatrists can treat hepatitis C.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13619.
    PubMed     Abstract available


  10. RODER C, Nguyen P, Harvey C, Wardrop M, et al
    Psychiatrists can treat hepatitis C.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13622.
    PubMed     Abstract available


  11. ROSATO V, Ascione A, Nevola R, Fracanzani AL, et al
    Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: a multicenter prospective study.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13617.
    PubMed     Abstract available


  12. CAVEN M, Baiano CX, Robinson EM, Stephens B, et al
    Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
    J Viral Hepat. 2021 Sep 15. doi: 10.1111/jvh.13614.
    PubMed     Abstract available


  13. MARCELLIN F, Di Beo V, Esterle L, Abgrall S, et al
    Post-HCV cure self-reported changes in physical activity, eating behaviors, and fatigue in people living with HIV (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2021 Sep 2. doi: 10.1111/jvh.13605.
    PubMed     Abstract available


  14. GARCIA-CEHIC D, Rando A, Rodriguez-Frias F, Gregori J, et al
    Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
    J Viral Hepat. 2021;28:1319-1324.
    PubMed     Abstract available


    August 2021
  15. PALMER AY, Chan K, Gold J, Layton C, et al
    A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13596.
    PubMed     Abstract available


  16. BALL LE, Agana B, Comte-Walters S, Rockey DC, et al
    Hepatitis C Virus Treatment with Direct Acting Antivirals Induces Rapid Changes in the Hepatic Proteome.
    J Viral Hepat. 2021 Aug 11. doi: 10.1111/jvh.13593.
    PubMed     Abstract available


  17. KNOP V, Hoppe D, Vermehren J, Troetschler S, et al
    Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 year follow-up of a prospective longitudinal study.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13587.
    PubMed     Abstract available


  18. HUPPE D, Stoehr A, Buggisch P, Mauss S, et al
    The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 Aug 2. doi: 10.1111/jvh.13586.
    PubMed     Abstract available


    July 2021
  19. SANTOS-LIMA C, Souza-Marques B, Vieira F, Schinoni MI, et al
    Neuropsychological effects of direct-acting antiviral treatment for HCV subjects: a systematic review.
    J Viral Hepat. 2021 Jul 28. doi: 10.1111/jvh.13584.
    PubMed     Abstract available


  20. WANG Y, Zhao Z, Zhang H, Lin Q, et al
    Estimating the transmissibility of hepatitis C: a modelling study in Yichang City, China.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13582.
    PubMed     Abstract available


  21. DEL ROSARIO A, Eldredge JD, Doorley S, Mishra SI, et al
    Hepatitis C Virus Care Cascade in Persons Experiencing Homelessness in the United States in the Era of Direct-Acting Antiviral Agents: A Scoping Review.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13583.
    PubMed     Abstract available


  22. OHKI T, Satov K, Kondo M, Goto E, et al
    Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13579.
    PubMed     Abstract available


  23. YOUSAFZAI MT, Bajis S, Alavi M, Grebely J, et al
    Treatment cascade of care for chronic hepatitis C virus infection globally: Systematic review and meta-analysis.
    J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13574.
    PubMed     Abstract available


  24. BISCHOFF J, Mauss S, Lutz T, Cordes C, et al
    Late presentation of chronic hepatitis C patients in the era of direct acting antivirals - Data from the German Hepatitis C-Registry.
    J Viral Hepat. 2021 Jul 21. doi: 10.1111/jvh.13576.
    PubMed     Abstract available


  25. BARDSLEY M, Heinsbroek E, Harris R, Croxford S, et al
    The Impact Of Direct-Acting Antivirals On Hepatitis C Viraemia Among People Who Inject Drugs In England; Real-World Data 2011-2018.
    J Viral Hepat. 2021 Jul 16. doi: 10.1111/jvh.13575.
    PubMed     Abstract available


  26. VARCHETTA S, Mele D, D'Ambrosio R, Perbellini R, et al
    A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C.
    J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13570.
    PubMed     Abstract available


  27. ERICE A, Varillas-Delgado D, Caballero C
    Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain).
    J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13564.
    PubMed     Abstract available


  28. MCGUIRE FH, Andre K, Bradsher ML, Harrison D, et al
    Willingness to participate in research among black patients with liver disease: A national cross-sectional study.
    J Viral Hepat. 2021;28:982-993.
    PubMed     Abstract available


    June 2021
  29. KIM HP, Edwards A, Reeve BB, Golin CE, et al
    Symptoms and Functioning Improve after Chronic Hepatitis C Cure as Assessed by the Memorial Symptom Assessment Scale and PROMIS Measures.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13561.
    PubMed     Abstract available


  30. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13562.
    PubMed     Abstract available


  31. KANG Q, Xu J, Luo H, Tan N, et al
    Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13558.
    PubMed     Abstract available


    May 2021
  32. BROWN C, Siegele M, Wright M, Cook C, et al
    Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs.
    J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13554.
    PubMed     Abstract available


  33. SMITH DA, Bradshaw D, Mbisa J, Manso CF, et al
    Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549.
    PubMed     Abstract available


  34. OHLENDORF V, Schafer A, Christensen S, Heyne R, et al
    Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting- results from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13546.
    PubMed     Abstract available


  35. LIU PC, Chan C, Huang YH, Chen YJ, et al
    Genetic Variants Associated With Serum Alanine Aminotransferase Levels Among Patients With Hepatitis C Virus Infection: A Genome-Wide Association Study.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13550.
    PubMed     Abstract available


  36. KIM S, Powell J, Naugle J, Ricco M, et al
    Patient-Reported Experiences with Direct Acting Antiviral Therapy in an Integrated Model of Hepatitis C Care in Homeless Shelters.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13544.
    PubMed     Abstract available


  37. MCDONALD SA, Barclay ST, Innes HA, Fraser A, et al
    Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543.
    PubMed     Abstract available


  38. COWAN E, Hardardt J, Brandspiegel S, Eiting E, et al
    Care cascade of patients with Hepatitis C and HIV identified by Emergency Department screening.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13529.
    PubMed     Abstract available


    April 2021
  39. CALVARUSO V, Petta S, Cacciola I, Cabibbo G, et al
    Liver and Cardiovascular Mortality After Hepatitis C Virus Eradication by DAA: data from RESIST-HCV Cohort.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13523.
    PubMed     Abstract available


  40. FIMMEL CJ, Khan MQ, Belopolsky Y, Imas P, et al
    Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524.
    PubMed     Abstract available


  41. HERNANDEZ C, Trujillo D, Turner CM, Sicro S, et al
    Reaching trans-women in San Francisco for efforts to eliminate hepatitis C.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13521.
    PubMed     Abstract available


  42. GOUTZAMANIS S, Spelman T, Harney B, Dietze P, et al
    Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13516.
    PubMed     Abstract available


  43. LEE TH, Chan A, Bryan W, Park L, et al
    Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.
    J Viral Hepat. 2021;28:630-636.
    PubMed     Abstract available


    March 2021
  44. BUTT AA, Yan P
    Natural History of Hepatitis C Virus Infection in a Large National Seroconversion Cohort in the Direct Acting Antiviral Agent Era: Results from ERCHIVES.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13507.
    PubMed     Abstract available


  45. LIU CH, Sun HY, Hsieh SM, Liu WC, et al
    Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct acting antivirals and antiretroviral therapy.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13502.
    PubMed     Abstract available


  46. BAIANO CX, Caven M, Robinson EM, Dillon JF, et al
    Evaluating and communicating hepatitis C cascades of care data in Tayside, Scotland: A journey towards elimination.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13505.
    PubMed     Abstract available


  47. MACGREGOR L, Ward Z, Martin NK, Nicholls J, et al
    The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13503.
    PubMed     Abstract available


  48. MACIAS J, Tellez F, de Los Santos I, Morano LE, et al
    Impact of recent drug use on the efficacy of Elbasvir/Grazoprevir for HCV-infected people on opioid agonist therapy.
    J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13496.
    PubMed     Abstract available


  49. JIANG JJ, Shiels MS, O'Brien TR
    Death Certificates Compared to SEER-Medicare Data for Surveillance of Liver Cancer Mortality Due to Hepatitis B or Hepatitis C Infection.
    J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13498.
    PubMed     Abstract available


  50. PERICOT-VALVERDE I, Rennert L, Heo M, Akiyama MJ, et al
    Rates of perfect self-reported adherence to direct-acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study.
    J Viral Hepat. 2021;28:548-557.
    PubMed     Abstract available


    February 2021
  51. BAR N, Levy S, Deutsch L, Leshno M, et al
    Hepatitis C related cognitive impairment: impact of viral and host factors and response to therapy.
    J Viral Hepat. 2021 Feb 23. doi: 10.1111/jvh.13492.
    PubMed     Abstract available


  52. BANDERA A, Lorenzini P, Taramasso L, Cozzi-Lepri A, et al
    The impact of DAA-mediated HCV eradication on CD4(+) and CD8(+) T lymphocyte trajectories in HIV/HCV coinfected patients: data from the ICONA Foundation Cohort.
    J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13488.
    PubMed     Abstract available


  53. VEGAS JJ, Flores-Herrera J, Latasa P, Garrido-Estepa M, et al
    Reduction in hepatitis C-related hospitalisations after the implementation of the Strategic Plan for Tackling Hepatitis C in the Spanish National Health System: regional level differences.
    J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13491.
    PubMed     Abstract available


  54. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
    Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care.
    J Viral Hepat. 2021 Feb 17. doi: 10.1111/jvh.13487.
    PubMed     Abstract available


  55. TOKUCHI Y, Suda G, Kimura M, Maehara O, et al
    Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
    J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13484.
    PubMed     Abstract available


  56. FRAZZONI L, Sikandar U, Mazzella G, Fuccio L, et al
    A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy.
    J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13486.
    PubMed     Abstract available


  57. SAHAKYAN Y, Lee-Kim V, Bremner KE, Bielecki JM, et al
    Impact of direct acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis C: systematic review and meta-analysis.
    J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13482.
    PubMed     Abstract available


  58. VERGARA M, Miquel M, Vela E, Cleries M, et al
    Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents.
    J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13479.
    PubMed     Abstract available


  59. KREKULOVA L, Honzak R, Riley LW
    Viral hepatitis C pandemic: challenges and threats to its elimination.
    J Viral Hepat. 2021 Feb 6. doi: 10.1111/jvh.13480.
    PubMed     Abstract available


  60. WEI YJ, Hsu PY, Lee JJ, Niu SW, et al
    Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uremic patients receiving hemodialysis in Taiwan- the FORMOSA-LIKE group.
    J Viral Hepat. 2021 Feb 3. doi: 10.1111/jvh.13477.
    PubMed     Abstract available


  61. PRITCHARD H, Hwang JP, Angelidakis G, Yibirin M, et al
    Hepatitis B Virus Reactivation in Cancer Patients Receiving Direct-Acting Antivirals for Hepatitis C Virus Infection.
    J Viral Hepat. 2021 Feb 1. doi: 10.1111/jvh.13478.
    PubMed     Abstract available


    January 2021
  62. LOCKART I, Hajarizadeh B, Alavi M, Davison S, et al
    Title: Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival.
    J Viral Hepat. 2021 Jan 22. doi: 10.1111/jvh.13475.
    PubMed     Abstract available


  63. WILDER JM, Evon DM, Jean Proeschold-Bell R, Yao J, et al
    Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression, and drinking motives.
    J Viral Hepat. 2021 Jan 21. doi: 10.1111/jvh.13474.
    PubMed     Abstract available


  64. SU X, Zhao X, Deng JL, Li SN, et al
    Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis.
    J Viral Hepat. 2021 Jan 16. doi: 10.1111/jvh.13469.
    PubMed     Abstract available


  65. CHEN B, Ma ZH, Xu B, Chang H, et al
    Evaluation of seven Rapid Diagnostic Tests for Detection of Hepatitis C Virus Antibodies in China.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13466.
    PubMed     Abstract available


  66. SHUMBUSHO F, Liu AF, Kateera F, Kabahizi J, et al
    Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13467.
    PubMed     Abstract available


  67. FRANCESCA ROMANA P, Francesco S, Massimo S, Antonio Giulio B, et al
    Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care center: results of the Telepass project.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13465.
    PubMed     Abstract available


    December 2020
  68. O'GORMAN P, Strahan O, Ferguson D, Monaghan A, et al
    Improvement in cognitive impairment following a 12-week aerobic exercise intervention in individuals with non-cirrhotic chronic hepatitis C.
    J Viral Hepat. 2020 Dec 28. doi: 10.1111/jvh.13460.
    PubMed     Abstract available


  69. FABBIANI M, Lombardi A, Colaneri M, Del Poggio P, et al
    High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
    J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13454.
    PubMed     Abstract available


  70. GORRIS M, van der Lecq BM, van Erpecum KJ, de Bruijne J, et al
    Treatment for Chronic Hepatitis E Virus Infection: A Systematic Review and Meta-analysis.
    J Viral Hepat. 2020 Dec 10. doi: 10.1111/jvh.13456.
    PubMed     Abstract available


  71. CHAN K, Elsum I, Gold J, Layton C, et al
    Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia.
    J Viral Hepat. 2020 Dec 1. doi: 10.1111/jvh.13447.
    PubMed     Abstract available


    November 2020
  72. TADA T, Toyoda H, Kumada T, Kurisu A, et al
    Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
    J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13444.
    PubMed     Abstract available


  73. WHITELEY D, Speakman E, Elliott L, Davidson K, et al
    Provider-related barriers and enablers to the provision of hepatitis C treatment by General Practitioners in Scotland: A behaviour change analysis.
    J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13443.
    PubMed     Abstract available


  74. RAZAVI H
    The cost effectiveness of hepatitis C virus elimination in low and middle-income countries.
    J Viral Hepat. 2020 Nov 17. doi: 10.1111/jvh.13442.
    PubMed     Abstract available


  75. WEINHEIMER-HAUS EM, Yu X, Singal AG, Naylor KB, et al
    Utilizing public health data to geotarget hepatitis C virus elimination approaches in urban and rural Michigan.
    J Viral Hepat. 2020 Nov 13. doi: 10.1111/jvh.13438.
    PubMed     Abstract available


  76. KIM D, Alshuwaykh OS, Cholankeril G, Wong RJ, et al
    Trends in Mortality in Hepatitis C Infection and Alcoholic Liver Disease based on Drug Overdose in the United States.
    J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13435.
    PubMed     Abstract available


  77. RIDRUEJO E, Pinero F, Mendizabal M, Silva M, et al
    Direct-Acting Antivirals Treatment Failure in Genotype 2 Hepatitis C chronic Infection.
    J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13433.
    PubMed     Abstract available


  78. KAPADIA SN, Katzman C, Fong C, Eckhardt BJ, et al
    Hepatitis C Testing and Treatment Uptake among Young People who Use Opioids in New York City: A Cross-Sectional Study.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13437.
    PubMed     Abstract available


  79. WU D, Hu S, Chen G, Jiao C, et al
    Association of Hepatitis C Infection and Risk of Kidney Cancer: A Systematic Review and Meta-analysis of Observational Studies.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13434.
    PubMed     Abstract available


  80. SHEU MJ, Liang FW, Lu TH
    Hepatitis C virus infection mortality trends according to three definitions with special concern for the baby boomer birth cohort.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13436.
    PubMed     Abstract available


    October 2020
  81. GALLACHER J, McPherson S
    Progress towards micro-elimination of hepatitis C in the custodial setting.
    J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13428.
    PubMed    


  82. FAHNOE U, Pedersen MS, Solund C, Ernst A, et al
    Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
    J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13430.
    PubMed     Abstract available


  83. GOYAL A, Perelson AS, Kandathil AJ, Quinn J, et al
    HIV influences clustering and intracellular replication of hepatitis C virus.
    J Viral Hepat. 2020 Oct 30. doi: 10.1111/jvh.13429.
    PubMed     Abstract available


  84. IBRAHIM ES, Abdel-Samiee M, Youssef MI, El-Shazly H, et al
    Variceal Recurrence 4 Years post Endoscopic Band Ligation in Hepatitis C Patients who Achieved Sustained Virological Response with Oral Direct Acting Antiviral Therapy.
    J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13426.
    PubMed     Abstract available


  85. REYES-URUENA J, Celly A, Moreno S, Majo X, et al
    Hepatitis C virus: testing rate and attrition at linkage to specialized care, Catalonia, Spain 2011-2016.
    J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13427.
    PubMed     Abstract available


  86. CHAN J, Kim JJ, Barrett BK, Hamadeh A, et al
    Cost-Effectiveness Analysis of Sofosbuvir and Velpatasvir in Chronic Hepatitis C Patients with Decompensated Cirrhosis.
    J Viral Hepat. 2020 Oct 16. doi: 10.1111/jvh.13419.
    PubMed     Abstract available


  87. LAURSEN TL, Villesen IF, Leeming DJ, Karsdal MA, et al
    Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.
    J Viral Hepat. 2020 Oct 15. doi: 10.1111/jvh.13416.
    PubMed     Abstract available


  88. MAFIRAKUREVA N, Lim AG, Khalid GG, Aslam K, et al
    Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
    J Viral Hepat. 2020 Oct 14. doi: 10.1111/jvh.13422.
    PubMed     Abstract available


  89. RAFIQUE S, Zahid S, Ali A, Tariq M, et al
    Genome wide methylation profiling of HCV pathogenesis to develop diabetes and diabetic complications.
    J Viral Hepat. 2020 Oct 13. doi: 10.1111/jvh.13417.
    PubMed     Abstract available


  90. POOLA S, Sanaka S, Sewell K, Tillmann HL, et al
    Hepatitis B Surface Antibody Titers and Hepatitis B Reactivation with Direct-Acting Antiviral Therapy for Hepatitis C.
    J Viral Hepat. 2020 Oct 12. doi: 10.1111/jvh.13421.
    PubMed     Abstract available


    September 2020
  91. MARTINEZ SANZ J, Vivancos MJ, Sanchez-Conde M, Gomez-Ayerbe C, et al
    Hepatitis C and HIV combined screening in primary care: a cluster randomized trial.
    J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13413.
    PubMed     Abstract available


  92. JOHNSON PJ, Berhane S, Walker AJ, Gordon FH, et al
    Impact Of Direct Acting Antiviral Agents On Liver Function In Patients With Chronic Hepatitis C Virus Infection.
    J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13408.
    PubMed     Abstract available


  93. ZHANG Y, Jiang X, Zhao Y, Xu Y, et al
    Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A Meta-analysis.
    J Viral Hepat. 2020 Sep 22. doi: 10.1111/jvh.13409.
    PubMed     Abstract available


  94. THAUNG YM, Simion Chasela C C, Chew KW, Minior T, et al
    Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus co-infected patients in Myanmar.
    J Viral Hepat. 2020 Sep 16. doi: 10.1111/jvh.13405.
    PubMed     Abstract available


  95. CHEN JY, Cheng PN, Chiu YC, Chiu HC, et al
    Persistent Augmentation of Central Arterial Stiffness Following Viral Clearance by Direct Acting Antivirals in Chronic Hepatitis C.
    J Viral Hepat. 2020 Sep 14. doi: 10.1111/jvh.13406.
    PubMed     Abstract available


  96. LINDGREN P, Lofvendahl S, Bradvik G, Weiland O, et al
    Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals.
    J Viral Hepat. 2020 Sep 8. doi: 10.1111/jvh.13398.
    PubMed     Abstract available


  97. VAN DIJK M, Drenth JPH
    Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination.
    J Viral Hepat. 2020 Sep 8. doi: 10.1111/jvh.13399.
    PubMed     Abstract available


  98. MIZOKAMI M, Liu LJ, Fujiyama N, Littman M, et al
    Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan.
    J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13395.
    PubMed     Abstract available


  99. PRINCE DS, Pipicella JL, Fraser M, Alvaro F, et al
    Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or "re-diagnose" infections is effective in Australia.
    J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13393.
    PubMed     Abstract available


    August 2020
  100. WADE AJ, Doyle JS, Draper B, Howell J, et al
    In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care.
    J Viral Hepat. 2020 Aug 29. doi: 10.1111/jvh.13391.
    PubMed     Abstract available


  101. VAN NUIL JI, Umutesi G, Shumbusho F, Kateera F, et al
    Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study).
    J Viral Hepat. 2020 Aug 28. doi: 10.1111/jvh.13386.
    PubMed     Abstract available


  102. SYED TA, Cherian R, Lewis S, Sterling RK, et al
    Telemedicine HCV Treatment in Department of Corrections Results in High SVR In Era of Direct-Acting Antivirals.
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13392.
    PubMed     Abstract available


  103. PFLUGER LS, Schulze Zur Wiesch J, Polywka S, Lutgehetmann M, et al
    Hepatitis delta virus propagation enabled by hepatitis C virus - scientifically intriguing; but is it relevant to clinical practice?
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13385.
    PubMed     Abstract available


  104. PHILLIPS C, O'Sullivan, Schulkind J, Jones CJ, et al
    Authors' reply to letter: In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care'.
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13389.
    PubMed     Abstract available


  105. SUNG JC, Wyatt B, Perumalswami PV, Branch A, et al
    Response to "Hepatitis C Cure Improved Patient-reported Outcomes in Patients with and without Liver Fibrosis in a Prospective Study at a Large Urban Medical Center".
    J Viral Hepat. 2020 Aug 25. doi: 10.1111/jvh.13381.
    PubMed     Abstract available


  106. GIULIANI R, Casigliani V, Fornili M, Sebastiani T, et al
    HCV micro-elimination in two prisons in Milan, Italy: a model of care.
    J Viral Hepat. 2020 Aug 20. doi: 10.1111/jvh.13376.
    PubMed     Abstract available


  107. MENDIZABAL M, Testa P, Rojas M, Colaci CS, et al
    Pilot study using the ECHO model to enhance linkage to care for patients with hepatitis C in the custodial setting.
    J Viral Hepat. 2020 Aug 19. doi: 10.1111/jvh.13374.
    PubMed     Abstract available


  108. MORA M, Goodyear T, Marcellin F, Shoveller J, et al
    Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13378.
    PubMed     Abstract available


  109. HAMADEH A, Haines A, Feng Z, Thein HH, et al
    Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada using population-based cohort studies.
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13373.
    PubMed     Abstract available


  110. RAHAL H, Boutros S, Farhat M, Kullar R, et al
    Estimating Pediatric Hepatitis C Prevalence in the United States.
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13377.
    PubMed     Abstract available


  111. BARRE T, Nishimwe ML, Protopopescu C, Marcellin F, et al
    Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort).
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13380.
    PubMed     Abstract available


  112. MESSINA V, Russo A, Parente E, Russo G, et al
    Innovative procedures for micro-elimination of hcv infection in persons who use drugs.
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13375.
    PubMed     Abstract available


  113. PERPINAN E, Perez-Del-Pulgar S, Londono MC, Marino Z, et al
    Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8(+) T cells after direct-acting antiviral therapies.
    J Viral Hepat. 2020 Aug 2. doi: 10.1111/jvh.13370.
    PubMed     Abstract available


    July 2020
  114. CASTRO FILHO E, Piedade J, Castro R, Luz PM, et al
    Effectiveness of direct-acting agents for chronic hepatitis C treatment in South America: a systematic review and meta-analysis.
    J Viral Hepat. 2020 Jul 24. doi: 10.1111/jvh.13364.
    PubMed     Abstract available


  115. IRVIN R, Ntiri-Reid B, Kleinman M, Agee T, et al
    Sharing the Cure: Building Primary Care and Public Health Infrastructure to Improve the Hepatitis C Care Continuum in Maryland.
    J Viral Hepat. 2020 Jul 15. doi: 10.1111/jvh.13360.
    PubMed     Abstract available


  116. DAI CY, Huang JF, Chuang WL, Yu ML, et al
    Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy: some issues.
    J Viral Hepat. 2020 Jul 5. doi: 10.1111/jvh.13358.
    PubMed     Abstract available


  117. DIMOVA RB, Rude E, Talal AH
    Age and Risk-Factor Based Serologic Screening for Hepatitis C Virus among an Urban, High-Risk Population.
    J Viral Hepat. 2020 Jul 2. doi: 10.1111/jvh.13359.
    PubMed     Abstract available


    June 2020
  118. NANGIA G, Vierling JM, Kwo P, Brown DD, et al
    Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: integrated analysis from clinical trials.
    J Viral Hepat. 2020 Jun 28. doi: 10.1111/jvh.13357.
    PubMed     Abstract available


  119. DALBENI A, Romano S, Bevilacqua M, Piccoli A, et al
    Beneficial effects of DAAs on cardiac function and structure in hepatitis C patients with low-moderate liver fibrosis.
    J Viral Hepat. 2020 Jun 27. doi: 10.1111/jvh.13355.
    PubMed     Abstract available


  120. CHEN YC, Thio CL, Kamangar F, Cox AL, et al
    Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting.
    J Viral Hepat. 2020 Jun 24. doi: 10.1111/jvh.13354.
    PubMed     Abstract available


  121. YOUSIF MM, Ahmed H, Elsadek HM, Shendi AM, et al
    Real-World Safety and Effectiveness Of Retreatment Of Egyptian Chronic Hepatitis C Patients Not Responding to NS5A Inhibitor-Based Therapies.
    J Viral Hepat. 2020 Jun 21. doi: 10.1111/jvh.13349.
    PubMed     Abstract available


  122. HWA YOUNG C, Mai Thi H, Kim KA, Cho H, et al
    Association between viral hepatitis infection and Parkinson's disease: A population-based prospective study.
    J Viral Hepat. 2020 Jun 17. doi: 10.1111/jvh.13346.
    PubMed     Abstract available


  123. SAINE ME, Szymczak JE, Moore TM, Bamford LP, et al
    Determinants of Stigma among Patients with Hepatitis C Virus (HCV) Infection.
    J Viral Hepat. 2020 Jun 5. doi: 10.1111/jvh.13343.
    PubMed     Abstract available


  124. MINA M, Underwood A, Eltahla A, Wu BR, et al
    Anti-Envelope antibody responses in highly-exposed seronegative individuals may be associated with protection from HCV infection.
    J Viral Hepat. 2020 Jun 4. doi: 10.1111/jvh.13339.
    PubMed     Abstract available


  125. JACK K, Linsley P, JamesThomson B, Irving WL, et al
    How do people in prison feel about opt-out hepatitis C virus testing?
    J Viral Hepat. 2020 Jun 2. doi: 10.1111/jvh.13338.
    PubMed     Abstract available


  126. KAPLAN DE, Medvedeva E, Serper M
    Care Quality and Outcomes among U.S. Veterans with Chronic Hepatitis B in the Hepatitis C Direct Acting Antiviral Era.
    J Viral Hepat. 2020 Jun 2. doi: 10.1111/jvh.13340.
    PubMed     Abstract available


  127. POLLOCK KG, McDonald SA, Gunson R, McLeod A, et al
    Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype.
    J Viral Hepat. 2020 Jun 1. doi: 10.1111/jvh.13337.
    PubMed     Abstract available


    May 2020
  128. CONNOLEY D, Francis-Graham S, Storer M, Ekeke N, et al
    Detection, stratification, and treatment of hepatitis C positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison.
    J Viral Hepat. 2020 May 25. doi: 10.1111/jvh.13336.
    PubMed     Abstract available


  129. DE LEDINGHEN V, Lusivika-Nzinga C, Bronowicki JP, Zoulim F, et al
    Sofosbuvir-based regimens are suboptimal in patients with genotype 2 chronic hepatitis C infection: Real-life experience from the HEPATHER ANRS CO22 cohort.
    J Viral Hepat. 2020 May 21. doi: 10.1111/jvh.13321.
    PubMed     Abstract available


  130. DIETZ J, Kalinina OV, Vermehren J, Peiffer KH, et al
    Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
    J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13322.
    PubMed     Abstract available


  131. YE W, Li X
    Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis.
    J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13323.
    PubMed     Abstract available


  132. KIM NG, Kullar R, Khalil H, Saab S, et al
    Meeting the WHO Hepatitis C Virus Elimination Goal: Review of Treatment in Pediatrics.
    J Viral Hepat. 2020 May 9. doi: 10.1111/jvh.13317.
    PubMed     Abstract available


  133. ZHANG M, O'Keefe D, Iwamoto M, Sann K, et al
    High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
    J Viral Hepat. 2020 May 2. doi: 10.1111/jvh.13311.
    PubMed     Abstract available


    April 2020
  134. CARRASCO I, Sainz T, Antoinette Frick M, de Ory SJ, et al
    Response to Direct Acting Antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients.
    J Viral Hepat. 2020 Apr 29. doi: 10.1111/jvh.13308.
    PubMed     Abstract available


  135. CHIU WN, Hung CH, Lu SN, Chen MY, et al
    Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection:a multicenter pooled analysis in Taiwan.
    J Viral Hepat. 2020 Apr 28. doi: 10.1111/jvh.13305.
    PubMed     Abstract available


  136. HONG CY, Sinn DH, Kang D, Paik SW, et al
    Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: Anationwide cohort study.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13304.
    PubMed     Abstract available


  137. LI YR, Chen WC, Tsai WL, Cheng JS, et al
    Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy without anti-viral prophylaxis.
    J Viral Hepat. 2020 Apr 16. doi: 10.1111/jvh.13302.
    PubMed     Abstract available


  138. AMOUGOU-ATSAMA M, Atangana PJA, Noah Noah D, Fewou Moundipa P, et al
    The role of hepatitis C virus genotypes and core mutations inhepatocellular carcinomain Cameroon.
    J Viral Hepat. 2020 Apr 16. doi: 10.1111/jvh.13303.
    PubMed     Abstract available


  139. ABU FREHA N, Wainstock T, Poupko L, Shemer Avni Y, et al
    Maternal hepatitis B or hepatitis C virus carrier s tatus and long-term infectious morbidity of the offspring: A population-based cohort study.
    J Viral Hepat. 2020 Apr 9. doi: 10.1111/jvh.13300.
    PubMed     Abstract available


  140. DESAI M, White E, Vora N, Gilson R, et al
    High incidence of Hepatitis C virus infection observed in the PROUD study of HIV pre-exposure prophylaxis.
    J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13297.
    PubMed     Abstract available


  141. TSENG CW, Wu SF, Chen CY, Ho YC, et al
    Characteristics of Regulatory T Cell Function in Patients with Chronic Hepatitis B and C Coinfection.
    J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13298.
    PubMed     Abstract available


    March 2020
  142. VAN SANTEN DK, Sacks-Davis R, Doyle JS, Scott N, et al
    Measuring hepatitis C virus elimination as a public health threat:beyond global targets.
    J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13294.
    PubMed     Abstract available


  143. JANJUA NZ, Wong S, Darvishian M, Butt ZA, et al
    The impact of SVR from direct acting antiviral and interferon- based treatments for HCV on hepatocellular carcinoma risk.
    J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13295.
    PubMed     Abstract available


  144. MEYER M, Bondy L, Koivu S, Koval J, et al
    New Hepatitis C Diagnoses in Ontario, Canada are associated with the Local Prescription Patterns of a Controlled Release Opioid.
    J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13292.
    PubMed     Abstract available


  145. BRADSHAW D, Vasylyeva TI, Davis C, Pybus OG, et al
    Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England.
    J Viral Hepat. 2020 Mar 1. doi: 10.1111/jvh.13286.
    PubMed     Abstract available


  146. DARVISHIAN M, Wong S, Binka M, Yu A, et al
    Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
    J Viral Hepat. 2020;27:243-260.
    PubMed     Abstract available


    February 2020
  147. BIELEN R, Koc OM, Busschots D, Verrando R, et al
    Validation of hepatitis C virus RNA detection using capillary blood by fingerprick (GenXpert system)- Hepatitis C fingerprick study.
    J Viral Hepat. 2020 Feb 27. doi: 10.1111/jvh.13284.
    PubMed     Abstract available


  148. DENG Y, Campbell F, Han K, Theodore D, et al
    Randomized Clinical Trials Towards a Single-Visit Cure for Chronic Hepatitis C: Oral GSK2878175 and Injectable RG-101 in Chronic Hepatitis C Patients and Long-Acting Injectable GSK2878175 in Healthy Participants.
    J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13282.
    PubMed     Abstract available


  149. KNOP V, Mauss S, Goeser T, Geier A, et al
    Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C (HCV) infection receiving direct acting antiviral therapy- results from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13280.
    PubMed     Abstract available


  150. MIRANDA AC, Mendez J, Serrao R, Vale F, et al
    Chronic hepatitis C treatment in HIV Co-infection in Portugal: Results from a cohort of 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group).
    J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13281.
    PubMed     Abstract available


  151. SHIHA G, Mousa N, Soliman R, Mikhail NN, et al
    Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study.
    J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13276.
    PubMed     Abstract available


  152. LIU Z, Mao X, Yu K, Suo C, et al
    Prevalence of HCV Resistance-Associated Substitutions amongTreatment FailurePatients receiving Direct-Acting Antiviral Agents.
    J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13270.
    PubMed     Abstract available


  153. CIMINI E, Sacchi A, Grassi G, Casetti R, et al
    Persistent gamma delta T-cell dysfunction in HCV/HIV co-infection despite direct-acting antiviral therapy induced cure.
    J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13277.
    PubMed     Abstract available


  154. HIGASHI RT, Jain MK, Quirk L, Rich NE, et al
    Patient and Provider-Level Barriers to Hepatitis C Screening and Linkage to Care: A Mixed-Methods Evaluation.
    J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13278.
    PubMed     Abstract available


  155. FALADE-NWULIA O, Ward KM, McCormick S, Mehta SH, et al
    Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care.
    J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13274.
    PubMed     Abstract available


    January 2020
  156. SHIHA G, Soliman R, Serwah A, Mikhail NN, et al
    A same day "test and treat" model for chronic HCV and HBV infection: Results from two community-based pilot studies in Egypt.
    J Viral Hepat. 2020 Jan 30. doi: 10.1111/jvh.13268.
    PubMed     Abstract available


  157. MD SAID R, Mohd Zain R, Chan HK, Soelar SA, et al
    Find the Missing Millions: Malaysia's Experience with Nationwide Hepatitis C Screening Campaign in the General Population.
    J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13267.
    PubMed     Abstract available


  158. CAVEN M, Robinson EM, Eriksen AJ, Fletcher EH, et al
    Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of People Who Inject Drugs, a service evaluation, the Hooked C project.
    J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13269.
    PubMed     Abstract available


  159. LIU CH, Yang SS, Peng CY, Lin WT, et al
    Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
    J Viral Hepat. 2020 Jan 25. doi: 10.1111/jvh.13265.
    PubMed     Abstract available


  160. TRAN TH, Nguyen BT, Nguyen TA, Pham TTP, et al
    Dried blood spots perform well to identify patients with active HCV infection in Vietnam.
    J Viral Hepat. 2020 Jan 24. doi: 10.1111/jvh.13263.
    PubMed     Abstract available


  161. POURMARZI D, Smirnov A, Hall L, Thompson H, et al
    Enablers and barriers for the provision of community-based HCV treatment: a case study of a real-world practice.
    J Viral Hepat. 2020 Jan 20. doi: 10.1111/jvh.13259.
    PubMed     Abstract available


  162. POORDAD F, Castro RE, Asatryan A, Aguilar H, et al
    Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir +/- Ribavirin in the TOPAZ-I and TOPAZ-II Trials.
    J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261.
    PubMed     Abstract available


  163. YAMAMICHI S, Miuma S, Wada T, Masumoto H, et al
    Deep sequence analysis of NS5A resistance-associated substitution changes in patients reinfected with the hepatitis C virus after liver transplantation.
    J Viral Hepat. 2020 Jan 2. doi: 10.1111/jvh.13256.
    PubMed     Abstract available


  164. FEDORCHENKO SV, Martynovych T, Klimenko Z, Yanchenko V, et al
    Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/ paritaprevir/ ritonavir, dasabuvir + sofosbuvir + r
    J Viral Hepat. 2020 Jan 2. doi: 10.1111/jvh.13254.
    PubMed     Abstract available


    December 2019
  165. IRVIN R, Chander G, Ward KM, Manogue S, et al
    Unreported Alcohol Use Was Common But Did Not Impact Hepatitis C Cure in HIV-Infected Persons Who Use Drugs.
    J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13251.
    PubMed     Abstract available


    November 2019
  166. BOYLE A, Marra F, Peters E, Datta S, et al
    Eight weeks of Sofosbuvir/Velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
    J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13239.
    PubMed     Abstract available


  167. CRESPO J, Cuadrado A, Perello C, Cabezas J, et al
    Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: data for designing a cost-effective elimination policy in Spain.
    J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13238.
    PubMed     Abstract available


  168. STARBIRD LE, Budhathoki C, Han HR, Sulkowski MS, et al
    Nurse case management to improve the hepatitis C care continuum in HIV co-infection: Results of a randomized controlled trial.
    J Viral Hepat. 2019 Nov 21. doi: 10.1111/jvh.13241.
    PubMed     Abstract available


  169. BHANDARI R, Morey S, Hamoodi A, Thompson C, et al
    High rate of hepatitis C re-infection following antiviral treatment in the North East England Prisons.
    J Viral Hepat. 2019 Nov 21. doi: 10.1111/jvh.13240.
    PubMed     Abstract available


  170. SUNG JC, Bosh C, Wyatt B, Miller M, et al
    Hepatitis C Cure Improved Patient-reported Outcomes in Patients with and without Liver Fibrosis in a Prospective Study at a Large Urban Medical Center.
    J Viral Hepat. 2019 Nov 19. doi: 10.1111/jvh.13234.
    PubMed     Abstract available


  171. BAJIS S, Grebely J, Hajarizadeh B, Applegate T, et al
    Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13233.
    PubMed     Abstract available


  172. CACCIOLA I, Borgia F, Filomia R, Pitrone C, et al
    Outcome of cutaneous psoriasis in hepatitis C virus infected patients treated with Direct Acting Antiviral therapy.
    J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13230.
    PubMed     Abstract available


  173. MCDONALD SA, Pollock KG, Barclay ST, Goldberg DJ, et al
    Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
    J Viral Hepat. 2019 Nov 6. doi: 10.1111/jvh.13232.
    PubMed     Abstract available


    October 2019
  174. CARDOZO EF, Ji D, Lau G, Schinazi RF, et al
    Disentangling the life-spans of hepatitis C virus infected cells and intracellular vRNA replication-complexes during direct acting antiviral therapy.
    J Viral Hepat. 2019 Oct 31. doi: 10.1111/jvh.13229.
    PubMed     Abstract available


  175. SAHAKYAN Y, Wong W, Yi Q, Thein HH, et al
    Long-term morbidity and mortality in a Canadian post-transfusion hepatitis C cohort: over 15 years of follow-up.
    J Viral Hepat. 2019 Oct 26. doi: 10.1111/jvh.13226.
    PubMed     Abstract available


  176. CARRAT F, Nahon P, Fontaine H, Pol S, et al
    Comparing Interferon-free with Interferon-based regimens in HCV patients: Rogers phenomenon and Simpson's paradox.
    J Viral Hepat. 2019 Oct 26. doi: 10.1111/jvh.13225.
    PubMed     Abstract available


  177. MARTIN P, Jadoul M, Pol S
    HCV in the Hemodialysis Population: treat now or later?
    J Viral Hepat. 2019 Oct 24. doi: 10.1111/jvh.13224.
    PubMed     Abstract available


  178. YANES-LANE M, Dussault C, Linthwaite B, Cox J, et al
    Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review.
    J Viral Hepat. 2019 Oct 22. doi: 10.1111/jvh.13220.
    PubMed     Abstract available


  179. DANIEL KE, Saeian K, Rizvi S
    Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment.
    J Viral Hepat. 2019 Oct 10. doi: 10.1111/jvh.13218.
    PubMed     Abstract available


  180. RUSSO FP, Zanetto A, Gambato M, Bortoluzzi I, et al
    Hepatitis C virus eradication with direct acting antiviral improves insulin resistance.
    J Viral Hepat. 2019 Oct 9. doi: 10.1111/jvh.13215.
    PubMed     Abstract available


    September 2019
  181. PHILLIPS C, Schulkind J, O'Sullivan M, Edelman N, et al
    Improving access to care for People Who Inject Drugs: Qualitative evaluation of Project ITTREAT, an integrated community hepatitis C service.
    J Viral Hepat. 2019 Sep 30. doi: 10.1111/jvh.13214.
    PubMed     Abstract available


  182. VAN SANTEN DK, Boyd A, Bruisten S, Sonder GJ, et al
    Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high-risk groups.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13205.
    PubMed     Abstract available


    July 2019
  183. MASON LMK, Veldhuijzen IK, Duffell E, van Ahee A, et al
    Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: a systematic review.
    J Viral Hepat. 2019 Jul 22. doi: 10.1111/jvh.13182.
    PubMed     Abstract available


  184. MARRONE A, Ciotti M, Rinaldi L, Adinolfi LE, et al
    Hepatitis B and C virus infection and risk of hematological malignancies.
    J Viral Hepat. 2019 Jul 20. doi: 10.1111/jvh.13183.
    PubMed     Abstract available


    May 2019
  185. WILLEMSE S, Smit C, Sogni P, Sarcletti M, et al
    Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV-patients with cirrhosis.
    J Viral Hepat. 2019 May 28. doi: 10.1111/jvh.13146.
    PubMed     Abstract available


    March 2019
  186. HAGA H, Saito T, Okumoto K, Tomita K, et al
    Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus are equivalent between genotype B and C in long term.
    J Viral Hepat. 2019 Mar 28. doi: 10.1111/jvh.13099.
    PubMed     Abstract available


    January 2019
  187. KIM HS, Yang JD, El-Serag HB, Kanwal F, et al
    Awareness of Chronic Viral Hepatitis in the United States: An Update from National Health and Nutrition Examination Survey.
    J Viral Hepat. 2019 Jan 10. doi: 10.1111/jvh.13060.
    PubMed     Abstract available


    September 2018
  188. LIU Z, Chen X, Zhang T
    Reply to "The epidemiology of hepatitis B virus infection in China".
    J Viral Hepat. 2018 Sep 21. doi: 10.1111/jvh.13007.
    PubMed     Abstract available


  189. ZHAO H
    The epidemiology of hepatitis B virus infection in China.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13004.
    PubMed     Abstract available


    July 2018
  190. PINTILIE H, Brook G
    Commentary: A review of risk of hepatitis B and C transmission through biting or spitting.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12976.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: